Belgian Capital Markets Stock News

Aedifica (ENXTBR:AED) posted a net profit margin of 62.1%, doubling last year’s margin of 31.1%. EPS growth soared by 115.1% as the company rebounded from a 5-year annual decline of 10.7%. Revenue is forecast to grow 3% annually, below the Belgian market's 8.4%, but earnings are projected to climb 18.8% per year, outpacing the market's 15.6% rate. Positive investor sentiment is likely to focus on the strong momentum in profitability and attractive valuation metrics, even as financial...

It's not a stretch to say that Barco NV's ( EBR:BAR ) price-to-earnings (or "P/E") ratio of 13.6x right now seems quite...

Solvay (ENXTBR:SOLB) is garnering attention as its advancements in bio-based and recyclable polymer technologies align with France’s fast-evolving market and regulatory push for circular economy solutions. Investors are watching how these initiatives shape long-term value. See our latest analysis for Solvay. Solvay’s recent advances in sustainable polymers come at an interesting time for shareholders, given the stock’s hefty 13.44% decline in share price so far this year. While the 1-year...

Fagron NV's ( EBR:FAGR ) price-to-earnings (or "P/E") ratio of 17.5x might make it look like a sell right now compared...

Nyxoah SA ( EBR:NYXH ) shareholders should be happy to see the share price up 14% in the last month. But that doesn't...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights The projected fair value for Spadel is €199 based on 2 Stage Free Cash Flow to Equity With €224 share...

With a price-to-sales (or "P/S") ratio of 0.6x Immobel SA ( EBR:IMMO ) may be sending very bullish signals at the...

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Cofinimmo (ENXTBR:COFB) reported a 20.9% annual decline in earnings over the past five years, but has just moved back into profitability despite a significant non-recurring loss of €52.6 million for the 12 months ending September 2025. Looking ahead, company earnings are forecast to grow at 13.1% per year, trailing the Belgian market average of 15.3%, while revenue is expected to decrease at an annual rate of -1.1% over the next three years. See our full analysis for Cofinimmo. Let’s see how...

Cmb.Tech (ENXTBR:CMBT) stock is catching investors’ attention today as recent trading patterns point to shifts in sentiment. Shares have seen mixed returns lately, bringing valuation and future prospects into sharper focus for the market. See our latest analysis for Cmb.Tech. While Cmb.Tech’s share price ticked higher over the past quarter, overall momentum has cooled, with a recent one-year total shareholder return of -41.5%. Investors seem to be weighing past volatility against the...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Most readers would already be aware that Viohalco's (EBR:VIO) stock increased significantly by 27% over the past three...

As the European market navigates a mixed landscape, with the pan-European STOXX Europe 600 Index inching higher amid dovish signals from the U.S. Federal Reserve and easing trade tensions, investors are keenly observing economic indicators like industrial production and labor market dynamics. In this environment, identifying promising small-cap stocks that can withstand volatility and capitalize on emerging opportunities is crucial for enhancing portfolio resilience.

Anheuser-Busch InBev (ENXTBR:ABI) shares have seen their ups and downs over the past few months. Recent price action reflects mixed sentiment from investors. The stock’s movement offers a window into the ongoing debates about value and future growth potential. See our latest analysis for Anheuser-Busch InBev. The latest share price of Anheuser-Busch InBev stands at $52.86, a level that reflects both recent volatility and the broader debate about the company’s long-term trajectory. Momentum...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Key Insights Institutions' substantial holdings in Azelis Group implies that they have significant influence over the...

Warehouses De Pauw (WDP) recently reported earnings for the nine months ended September 30, 2025, posting sales of €335.6 million, up from €284.28 million a year earlier, but net income fell to €246.68 million compared to €306.32 million in the prior period. In addition, Clifford Chance announced it advised on WDP’s inaugural €500 million green senior unsecured bond issuance under its EMTN programme, following a Moody’s upgrade of WDP’s long-term issuer rating to A3 with a stable...

On October 13, 2025, UCB announced that Neurology had published favorable results from a multicenter retrospective chart review study of its investigational pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d), showing that 29% (6 out of 21) of treated individuals experienced reduced need for ventilatory support and most adverse events were mild. An interesting aspect of the study is the potential clinical impact on this rare neuromuscular...

Warehouses De Pauw (ENXTBR:WDP) just posted results for the nine months ending September 2025. Sales climbed compared to last year, while net income and earnings per share slipped during the same stretch. See our latest analysis for Warehouses De Pauw. Warehouses De Pauw’s 8.5% share price return over the last 90 days suggests growing optimism, even though the total shareholder return for the past year has been a more modest 2.1%. In the broader context, recent gains appear to reflect renewed...

UCB (ENXTBR:UCB) just shared results from a multicenter study published in Neurology, highlighting that a new investigational therapy for TK2 deficiency showed some treated patients needed less ventilatory support, with mostly mild side effects. See our latest analysis for UCB. Despite some recent pullbacks, UCB’s share price has surged with a 22.5% gain over the past month and a remarkable 42.2% in the last 90 days. Momentum appears to be on the upswing, and when you look at the long game,...